New York State Assembly

 
•  Summary 
 
•  Actions 
 
•  Committee Votes 
 
•  Floor Votes 
 
•  Memo 
 
•  Text 
 
•  LFIN 
 
•  Chamber Video/Transcript 

A00333 Summary:

A00333 Actions:

A00333 Committee Votes:

Committee:HEALTH   Chair:Gottfried      
DATE:01/26/2021AYE/NAY:26/0  Action: Favorable refer to committee Ways and Means        
Gottfried
Aye
Byrne
Aye
Galef
Aye
McDonough
Aye
Dinowitz
Aye
Byrnes
Aye
Cahill
Aye
Ashby
Aye
Paulin
Aye
Miller
Aye
Cymbrowitz
Aye
Salka
Aye
Gunther
Aye
Jensen
Aye
Rosenthal L 
Aye
Hevesi
Aye
Steck
Aye
Abinanti
Aye
Braunstein
Aye
Solages
Aye
Bichotte Hermel
Aye
Barron
Aye
Sayegh
Aye
Rosenthal D 
Aye
McDonald
Aye
Reyes
Aye

Committee:WAYS AND MEANS   Chair:Weinstein      
DATE:04/28/2021AYE/NAY:34/0  Action: Favorable         
Weinstein
Aye
Ra
Aye
Glick
Aye
Fitzpatrick
Aye
Nolan
Excused
Hawley
Aye
Pretlow
Aye
Montesano
Aye
Perry
Aye
Blankenbush
Aye
Colton
Aye
Norris
Aye
Cook
Aye
Brabenec
Aye
Cahill
Aye
Palmesano
Aye
Aubry
Aye
Byrne
Aye
Cusick
Aye
Ashby
Aye
Benedetto
Aye
Weprin
Aye
Rodriguez
Aye
Ramos
Aye
Braunstein
Aye
McDonald
Aye
Rozic
Aye
Dinowitz
Aye
Joyner
Aye
Magnarelli
Aye
Zebrowski
Aye
Bronson
Aye
Dilan
Aye
Seawright
Aye
Hyndman
Aye

A00333 Floor Votes:

A00333 Text:

 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                           333
 
                               2021-2022 Regular Sessions
 
                   IN ASSEMBLY
 
                                       (Prefiled)
 
                                     January 6, 2021
                                       ___________
 
        Introduced  by  M. of A. L. ROSENTHAL, PERRY -- Multi-Sponsored by -- M.
          of A. COOK -- read once and referred to the Committee on Health
 
        AN ACT to amend the public authorities law, in relation to  establishing
          a  lymphedema  and  lymphatic diseases research grants program; and to
          amend the state finance law, in relation to  creating  the  lymphedema
          and lymphatic diseases research and education fund
 
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1. The public authorities law  is  amended  by  adding  a  new
     2  section 3153-a to read as follows:
     3    §  3153-a.  Lymphedema and lymphatic diseases research grants program.
     4  1. The foundation shall, within available appropriations, establish  the
     5  lymphedema  and  lymphatic  diseases  research grants program, hereafter
     6  "grants program." The grants program shall be administered by the  foun-
     7  dation,  in  consultation  with  the  department  of health. Such grants
     8  program funds shall be used to provide financial assistance in the  form
     9  of  grants,  not to exceed fifty thousand dollars per grant, to New York
    10  state biomedical research institutions for working  capital  to  further
    11  new  and  emerging research and development for the diagnosis and treat-
    12  ment of lymphedema and lymphatic diseases. Such grants shall be  awarded
    13  on a competitive basis to biomedical research institutions responding to
    14  requests for proposals issued by the foundation when funds are appropri-
    15  ated.
    16    2.  (a)  "Biomedical research institution" shall mean a not-for-profit
    17  university, college, hospital, private or  federal  research  laboratory
    18  located  in  New  York  state,  or  a  consortium of such entities, that
    19  conducts an intensive and ongoing program of  research  and  development
    20  directly related to lymphedema and/or lymphatic diseases research.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD00469-01-1
        A. 333                              2
 
     1    (b)  "Lymphedema" shall mean an accumulation of lymphatic fluid in the
     2  interstitial tissue that causes swelling, most often in the arms  and/or
     3  legs, and occasionally in other parts of the body, from any cause.
     4    (c)  "Lymphatic diseases" shall include but not be limited to:  insuf-
     5  ficiency of lymphatic circulatory function  (to  include  all  forms  of
     6  lymphedema),  lipedema,  complex  congenital  diseases  of the lymphatic
     7  vasculature,  including  lymphangiomatosis,   lymphangioleio-myomatosis,
     8  lymphangiectasias,  lymphangiomas,  cystic  hygromas,  Gorham's disease,
     9  lymphangiosarcoma, and complex vascular/lymphatic malformations.
    10    3. In addition to such other criteria as the foundation may  adopt  in
    11  rules  and  regulations for the consideration of applications for grants
    12  pursuant to subdivision one of this section, the foundation shall:
    13    (a) determine that the applicant is unable to obtain sufficient  fund-
    14  ing  on  reasonable terms from other public or private sources to permit
    15  the institution's planned investment to  proceed  without  the  required
    16  assistance;
    17    (b) give priority to those applications for assistance from biomedical
    18  research institutions that secure private support for research or commit
    19  new  resources  to  the  expansion  of lymphedema and lymphatic diseases
    20  research; and
    21    (c) consider the potential long term economic benefits to the state of
    22  awarding the specific grant and whether  the  grant  will  result  in  a
    23  reasonable  likelihood  of  success in meeting the purposes for which it
    24  was sought by the applicant.
    25    4. The foundation, in consultation with the department of health,  may
    26  apply to the national institutes of health, the United States department
    27  of health and human services, and other appropriate federal, public, and
    28  private  entities  for  funding. Such monies shall be deposited into the
    29  lymphedema and lymphatic diseases research and  education  fund,  estab-
    30  lished pursuant to section ninety-nine-ii of the state finance law.
    31    5.  The  foundation  shall  submit to the governor, the speaker of the
    32  assembly, the temporary president of the senate, and to any other  state
    33  legislator  at  his  or  her  request, a report on the grants program by
    34  September first, two thousand twenty-three and annually thereafter. Such
    35  report shall include, for each grant awarded, the name and  location  of
    36  the  recipient,  a description of the product, device, technique, system
    37  or process being researched and developed, the recipient's  relationship
    38  to  the research institution, the amount and use of the grant, the total
    39  project cost, and such other information as the  foundation  shall  deem
    40  appropriate. Such report shall also include a list of all applicants and
    41  their  contact information, regardless of receiving a grant, in order to
    42  help demonstrate the need for future funds.
    43    6. Nothing in this section shall require the  foundation  to  disclose
    44  any  matters  involving confidential intellectual property or work prod-
    45  uct, whether patentable or not, including any  formula,  plan,  pattern,
    46  process, tool, mechanism, compound, procedure, production data or compi-
    47  lation of information, which is not patented, but which is known only to
    48  certain  individuals  who are using it to fabricate, produce or compound
    49  an article of trade or service having commercial value and  which  gives
    50  its  user an opportunity to obtain a business advantage over competitors
    51  who do not know it or use it.
    52    § 2. The state finance law is amended by adding a new section 99-ii to
    53  read as follows:
    54    § 99-ii. Lymphedema and  lymphatic  diseases  research  and  education
    55  fund. 1. There is hereby established in the joint custody of the commis-
    56  sioner of taxation and finance and the comptroller, a special fund to be
        A. 333                              3
 
     1  known  as  the  lymphedema and lymphatic diseases research and education
     2  fund, hereafter the "fund".
     3    2.  Such  fund  shall consist of all monies appropriated, credited, or
     4  transferred thereto from any other  fund  or  source  pursuant  to  law.
     5  Nothing contained in this section shall prevent the state from receiving
     6  grants,  gifts  or  bequests  for the purposes of the fund as defined in
     7  this section and depositing them into the fund according to law.
     8    3. Monies of the fund shall be expended only for lymphedema and  lymp-
     9  hatic  diseases  research and education projects approved by the depart-
    10  ment of health.
    11    4. (a) "Lymphedema" shall mean an accumulation of lymphatic  fluid  in
    12  the  interstitial  tissue  that  causes swelling, most often in the arms
    13  and/or legs, and occasionally in other parts of the body, regardless  of
    14  cause.
    15    (b)  "Lymphatic diseases" shall include but not be limited to:  insuf-
    16  ficiency of lymphatic circulatory function  (to  include  all  forms  of
    17  lymphedema),  lipedema,  complex  congenital  diseases  of the lymphatic
    18  vasculature,  including  lymphangiomatosis,   lymphangioleio-myomatosis,
    19  lymphangiectasias,  lymphangiomas,  cystic  hygromas,  Gorham's disease,
    20  lymphangiosarcoma, and complex vascular/lymphatic malformations.
    21    (c)  "Lymphedema  and  lymphatic  diseases  research   and   education
    22  projects" shall mean research by qualified researchers, as determined by
    23  the  department of health, to stimulate research on the pathogenesis and
    24  new treatments for lymphedema and lymphatic diseases. Education projects
    25  are those projects which promote and provide information  on  lymphedema
    26  and  lymphatic  diseases  including:   prevention, diagnosis, treatment,
    27  long-term chronic care, and/or research by  qualified  organizations  as
    28  determined by the department of health.
    29    5.  Monies  shall be payable from the fund on the audit and warrant of
    30  the comptroller on vouchers approved and certified by  the  commissioner
    31  of health.
    32    6.  To the extent practicable, the commissioner of health shall ensure
    33  that all monies received during a fiscal year are expended prior to  the
    34  end of that fiscal year.
    35    § 3. This act shall take effect immediately.